ASHLEY GORMLEY: Open Payments
NPI 1710768734 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$914 in 62 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,141 · 2025 $914
Food & beverage: $894Education: $20
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $181 |
| Janssen Biotech, Inc. | 15 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $156 |
| Madrigal Pharmaceuticals | 5 | $100 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| QOL Medical, LLC | 2 | $41 |
| Lilly USA, LLC | 2 | $39 |
| GENZYME CORPORATION | 1 | $33 |
| Ardelyx, Inc. | 2 | $30 |
Products named: TREMFYA, ENTYVIO, REZDIFFRA, SKYRIZI, RINVOQ, EOHILIA, IQIRVO, XIFAXAN.
Industry payments across NE — which companies pay providers there.
